


BioStar Capital is a value-add investment firm focused on transformational medical device technologies in cardiovascular and orthopaedic medicine. Combining the insight of experienced investment professionals and world-renowned medical thought leaders, BioStar Capital identifies proprietary technologies that serve unmet patient needs and fit the acquisition criteria of leading medical device companies. BioStar Capital fills an important gap in medical device innovation and provides operational skills and clinical expertise in addition to capital, enabling the firm to actively mitigate risk, optimize product development, and secure successful exit. The firm has invested in over 30 med-tech companies, many of which have been acquired by a major medical device manufacturer.
BioStar News
Portfolio News
January 15, 2021
DeviceTalks Weekly features Mark Toland, BioStar Entrepreneur-in-Residence: Digging into the Digital Medtech & Surgical Worlds
September 15, 2020
Mark Toland, Former CEO of Siemens-Owned Corindus, Joins BioStar Capital as Partner and Entrepreneur in Residence
April 6, 2021
TransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System
April 1, 2021
Trice Medical continues mission of making elective procedures more efficient through the acquisition of Tenex Health
